Fast‑Track Psychedelics: New Rules for Treating Depression and PTSD
President Trump recently signed an executive order urging the FDA and other agencies to speed up research on psychedelics, which remain illegal under federal law. The agency has issued priority review vouchers to two firms developing psilocybin for treatment‑resistant depression, and a third voucher went to a company working on methylone—a chemical akin to MDMA—for post‑traumatic stress disorder. While these vouchers do not guarantee approval, they shorten the review time from months to weeks.
The move comes amid growing support for these substances among Trump’s base, including veterans and followers of the Make America Healthy Again campaign led by Health Secretary Robert Kennedy Jr. Kennedy has publicly promised that psychedelics could be available for difficult psychiatric conditions within a year, and several of his aides have expressed enthusiasm.
The FDA’s special treatment may bring renewed scrutiny of its National Priority Voucher program. Critics argue that the vouchers have favored companies with political ties to the White House and those willing to lower prices. Meanwhile, a separate FDA decision allows initial testing of an ibogaine‑related drug for alcohol use disorder. Ibogaine, derived from an African shrub, has a controversial safety record but is popular among veterans seeking treatment for trauma and addiction.
High‑profile figures such as podcaster Joe Rogan—who met with the president about ibogaine—highlight how political influence may accelerate drug approval processes. Rogan’s endorsement of the substance just before the 2024 election was noted by White House aides as a potential factor in his campaign success.
Although psychedelics like LSD, psilocybin and MDMA are classified as Schedule I substances with no accepted medical use, a wave of small companies—often backed by Silicon Valley investors—has entered the field. Tech billionaire Peter Thiel, who has donated to both Trump and Vice President JD Vance, is one example of an investor supporting psychedelic research.
The policy shift reflects a broader trend of reexamining the legal status of mind‑altering drugs and their potential therapeutic benefits. However, questions remain about safety, regulation, and the influence of politics on scientific progress.
